



Luxembourg, 20 December 2024

Environmental and Social Completion Sheet (ESCS)

Overview

Project Name:	UNIVERCELLS - COVID (IDFF)
Project Number:	2020-0423
Country:	Belgium
Project Description:	The project concerns investments into an innovative and versatile vaccine manufacturing facility as well as process development and manufacturing scale up activities to enable the production of large volumes of prophylactic vaccines against SARS-CoV-2 as well as in co-development of a pipeline of COVID-19 vaccines.

Summary of Environmental and Social Assessment at Completion

EIB notes the following Environmental and Social performance and key outcomes at Project Completion.

The project mainly covered investments in RDI that were carried out in the Promoter's existing facilities or other research centres already authorised

The promoter's R&D facilities and practices are in compliance with relevant national and EU regulations and the promoter maintains adequate internal procedures and management practices. The use of animal testing is minimised and in line with the EU Directive 2010/63/EU. In addition, The Company has adequate policies and procedures in place to outsource and manage clinical trials in different regions of the world in accordance with the EU 536/2014 regulation. The clinical trials which are sponsored by the project are performed under-regulated and strictly controlled conditions, in existing specialised facilities which are regularly inspected by competent authorities - EMA in Europe and/or national equivalent bodies in the rest of the world (e.g. FDA).

No significant environmental or social issues were noted.

Summary opinion of Environmental and Social aspects at completion:

EIB is of the opinion, based on reports from the promoter and site visits by the EIB team, that the Project has been implemented in line with EIB Environmental and Social Standards, applicable at the time of appraisal.